Home » FDA Extends Comment Period on Combination Products Rule
FDA Extends Comment Period on Combination Products Rule
Requests from stakeholders have led the FDA
to extend the comment period to Feb. 5 on a proposed rule on good manufacturing practices (GMPs) for combination products. Under the proposed rule, companies could develop written procedures for a
streamlined system to show compliance with GMPs for drugs or biologics and quality system requirements for devices.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
07May
-
14May
-
30May